Dear Sir, In their recent article E H. Hendriksen et al. [1] report similar percentages of abnormal neurophysiological test results in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients with subclinical (asymptomatic) neuropathy, suggesting that there are no differences in the manifestation of neuropathy in relation to the type of diabetes.
We have assessed peripheral nerve function using nerve conduction and quantitative sensory tests in 130 Type 1 and 45 Type 2 diabetic patients, classified according to the recommendations of the National Diabetes Data Group [2] , without neuropathic s}maptoms [age: 28 (14-62) and 54 (40-75) years (median, range), duration of diabetes: 10 (1-44) and 9 (1-30)years] and in 65 Type i and 91 Type 2 diabetic subjects with symptoms of peripheral n europathy [age: 44 (15-69) and 63 (40-82) years, duration of diabetes: 20 (2-53) and 12 (1-50) years]. Age-dependent normal ranges for the neurophysiological tests have been established in 57 (nerve conduction) and 70 (thermal, pain, and vibration sensation thresholds) health}, subjects as previously described [3, 4] .
The percentages of abnormal test results in the four groups studied are shown in Table 1 . In both the asymptomatic and symptomatic Type 2 diabetic patients the thermal discrimination threshold on the hand, pain perception threshold to heat and cold on the foot, metacarpal and malleolar vibration perception threshold, and peroneal motor nerve conduction were significantly more frequently abnormal as compared with the corresponding group of subjects with Type 1 diabetes (p < 0.05). In addition, among the patients with symptomatic neuropathy, the group with Type 2 diabetes showed a significantly higher percentage of abnormalitites for the These results suggest a higher degree of both small and large nerve fibre dysfunction in the upper and lower limbs among Type 2 compared to Type 1 diabetic patients with either subclinical and symptomatic peripheral neuropathy. The most prominent deficits were noted for nerve conduction and thermal discrimination and vibration perception thresholds in the lower limbs, indicating a parallel involvement of small and large nerve fibre dysfunction in both subclinical and symptomatic diabetic neuropathy. One possible explanation for the observed differences could be a histopathological heterogeneity of the distal symmetrical neuropathy, with predominant axo-glial dysjunction in Type i diabetes in contrast to focal fibre loss and Wallerian degeneration in Type 2 diabetes [5] . It is conceivable the endoneurial microvascular abnormalities play a reinforcing role in the pathogenesis of neuropathy in Type 2 diabetes. Such distinct morphological findings may reflect a pathogenetic variability in relation to the type of diabetes, which could have been responsible for the quantitative differences observed in our study.
Recently The absolute insulin levels in nmol/1 reported in this paper are incorrect, through an error which is systematic and, therefore, does not alter the conclusions. The error is due to a misleading label on a (WHO) international insulin standard supplied by the National Institute of Biological Standards Control. The vial was labelled as "5.4699 mg of this preparation when diluted to i ml will contain 3 IU insulin activity". It has come to our attention that the weight, in this particular case, refers to the total protein content not the insulin content. The National Institute have been informed of this potential source of error and they have provided us with the insulin content of that standard. The labels on the present standards from the Institute refer to insulin activity per unit weight of insulin. To obtain the correct values for insulin in nmol/1 or pmol/1 all insulin levels in the above paper should be multiplied by 0.023766 or 23.766 respectively. conveyed the incorrect impression that the increased NADH: NAD + ratio consequent on increased oxidation of sorbitol to fructose was directly coupled to increased formation of dihydroxyacetone phosphate from glyceraldehyde-3-phosphate. The proposed link is in fact indirect, with the increased NADH:NAD + ratio tending to inhibit glyceratdehyde-3-phosphate dehydrogenase, with its consequent increased diversion of glyceraldehyde-3-phosphate to dihydroxyacetone phosphate and its subsequent conversion to diacylglycerol, either as indicated in Figure A error has been made in our sequence of human Beta-cell glucokinase in Figure 1 . Amino acid 171 should be Phe (TTC). The correct sequence has been submitted to the GenBank database. The accession number is M88011. We regret any inconvenience caused by this mistake.
